Disruption of enhancer-driven S100A14 expression promotes esophageal carcinogenesis
-
Published:2022-10
Issue:
Volume:545
Page:215833
-
ISSN:0304-3835
-
Container-title:Cancer Letters
-
language:en
-
Short-container-title:Cancer Letters
Author:
Li Xukun,
Ding Fang,
Wang Luhua,
Chen Hongyan,
Liu ZhihuaORCID
Subject
Cancer Research,Oncology
Reference44 articles.
1. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study;Huang;Lancet Oncol.,2020
2. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial;Kato;Lancet Oncol.,2019
3. Super-enhancers in the control of cell identity and disease;Hnisz;Cell,2013
4. Master transcription factors and mediator establish super-enhancers at key cell identity genes;Whyte;Cell,2013
5. A pan-cancer analysis of enhancer expression in nearly 9000 patient samples;Chen;Cell,2018
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献